Santarus, a specialty biopharmaceutical company, has reported positive results from a Phase III study of rifamycin SV MMX in patients with travelers’ diarrhoea.

The study, which is designed to evaluate the safety and efficacy of rifamycin SV MMX, has met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers’ diarrhoea.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Santarus research and development executive vice president Dr Wendell Wierenga said the results are a key milestone in developing the drug for the US market.

"Rifamycin SV is an investigational broad spectrum, non-systemic antibiotic that has been used for more than 20 years in Europe in both intravenous and intramuscular forms, but is considered a new chemical entity in the US," Wierenga said.

According to the study data, in the intent-to-treat population, the median TLUS was 46.0 hours for rifamycin SV, compared to 68.0 hours for placebo, with similar results in the per protocol population.

See Also:

Rifamycin SV was generally well tolerated in the study and the frequency of treatment emergent adverse events was similar to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Santarus previously signed a licensing deal with Cosmo Technologies to develop and commercialise rifamycin SV MMX in the US.

Cosmo’s European development partner, Dr. Falk Pharma, is conducting a second Phase III study to evaluate the efficacy of rifamycin SV versus ciprofloxacin with the primary endpoint of TLUS in patients with travelers’ diarrhoea.

Anticipating positive second Phase III study results, Santarus and Dr. Falk plan to share the clinical data from their respective studies to include in both company’s regulatory submissions.